Microtubule stabilising agents for cancer chemotherapy

Bibliography

• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Altmann K-H, Gertsch J. Anticancer drugs from nature—natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007;24:327-57
   PubMed Web of Science ®Google Scholar
• Molodtsov MI, Ermakova EA, Shnol EE, et al. A molecular-mechanical model of the microtubule. Biophys J 2005;88:3167-79
   Google Scholar
• He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today 2001;6:1153-64
   PubMed Web of Science ®Google Scholar
• Altmann K-H. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 2001;5:424-31
   Google Scholar
• Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone. Cancer Res 2003;63:6026-31
   PubMed Web of Science ®Google Scholar
• Honore S, Kamath K, Braguer D, et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 2004;64:4957-64
   PubMed Web of Science ®Google Scholar
• Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13:2849-54
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25
   PubMed Web of Science ®Google Scholar
• Trielli MO, Andreassen PR, Lacroix FB, et al. Differential taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 1996;135:689-700
   PubMed Web of Science ®Google Scholar
• Chen J-GC, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;14:1935-8
   Google Scholar
• Chen J-GC, Yang C-PHY, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003;15:7891-9
   Google Scholar
• Kim T-J, Lim Y, Kim D-W, et al. Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins. Vasc Pharmcol 2007;47:229-37
   Google Scholar
• Rodi DJ, Janes RW, Sanganee HJ, et al. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 1999;285:197-203
   PubMed Web of Science ®Google Scholar
• Byrd CA, Bornmann W, Erdjument-Bromage H, et al. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc Natl Acad Sci USA 1999;96:5645-50
   PubMed Web of Science ®Google Scholar
• Bhat N, Perera PY, Carboni JM, et al. Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression. J Immunol 1999;162:7335-42
   PubMed Web of Science ®Google Scholar
• Boehmerle W, Splittgerber U, Lazarus MB, et al. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc Natl Acad Sci USA 2006;103:18356-61
   PubMed Web of Science ®Google Scholar
• Aoki S, Morohashi K, Sunoki T, et al. Screening of paclitaxel-binding molecules from a library of random Peptides displayed on T7 phage particles using paclitaxel-photoimmobilized resin. Bioconjug Chem 2007;18:1981-6
   PubMed Web of Science ®Google Scholar
• Zimmer SM, Liu J, Clayton JL, et al. Paclitaxel binding to human and murine MD-2. J Biol Chem 2008;283:27916-26
   Google Scholar
• André N, Braguer D, Brasseur G, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000;60:5349-53
   PubMed Web of Science ®Google Scholar
• Khawaja NR, Carré M, Kovacic H, et al. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol 2008;74:1072-83
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents VI. The isolation and structure of taxol a novel anti-leukemic and anti-tumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7
   PubMed Web of Science ®Google Scholar
• Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7
   PubMed Web of Science ®Google Scholar
• Nogales E, Wolf SG, Khan IA, et al. Structure of tubulin at 6.5Å and location of the taxol-binding site. Nature 1995;375:424-7
   PubMed Web of Science ®Google Scholar
• Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000;69:277-302
   PubMed Web of Science ®Google Scholar
• Safavy A. Taxane derivatives for targeted therapy of cancer. US6191290; 2001
   Google Scholar
• Sohn Y-S, Ji D-E, Jun Y-J, Lee H-J. Water soluble micelle-forming and biodegradable cyclotriphosphazene-taxol conjugate anticancer agent and preparation method thereof. US20070292384; 2007
   Google Scholar
• Polizzi D, Pratesi G, Monestiroli S, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 2000;6:2070-4
   PubMed Web of Science ®Google Scholar
• Sampath D, Discafani CM, Loganzo F, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003;2:873-84
   PubMed Web of Science ®Google Scholar
• Beeram M, Takinoto CH, Gadgeel S, et al. Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. J Clin Oncol 2004;22:2028
   Google Scholar
• Broker LE, deVos FY, Gall H, et al. A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors. J Clin Oncol 2004;22:2029
   Google Scholar
• Sampath D, Greenberger LM, Beyer C, et al. Preclinical pharmacologic evaluation of MST-997, and orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res 2006;12:3459-69
   Google Scholar
• Ferlini C, Gallo D, Scambia G. New taxanes in development. Expert Opin Investig Drugs 2008;17:335-47
   PubMed Web of Science ®Google Scholar
• Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007;2:920-42
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Takara K, Tanigawara Y, et al. Interaction of docetaxel (“Taxotere”) with human P-glycoprotein. Jpn J Cancer Res 1999;90:1380-6
   PubMedGoogle Scholar
• Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001;298:1236-42
   PubMed Web of Science ®Google Scholar
• Yang C-G, Barasoain I, Li X, et al. Overcoming tumor drug resistance with high-affinity taxanes: a SAR study of C2-modified 7-acyl-10-deacetyl cephalomannines. ChemMedChem 2007;2:691-701
   Google Scholar
• Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: dose TUBB3 work? Curr Cancer Drug Targets 2007;7:704-12
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Kuo DY-S, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93
   PubMed Web of Science ®Google Scholar
• Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;298:298-305
   Google Scholar
• Dumontet C, Isaac S, Souquet P-J, et al. Expression of class III β-tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005;92:E25-30
   PubMedGoogle Scholar
• Sève P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7
   PubMed Web of Science ®Google Scholar
• Banerjee A. Increased levels of tyrosinated α-, βIII-, and βIV-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002;293:598-601
   Google Scholar
• Shalli K, Brown I, Heys SD, Schofield AC. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005;19:1299-301
   PubMed Web of Science ®Google Scholar
• Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97:813-20
   PubMed Web of Science ®Google Scholar
• Agoulnik S, Kuznetsov G, Littlefield BA. Tubulin isotype screening in cancer therapy using hemiasterlin analogs. US20060148014; 2006
   Google Scholar
• Agoulnik S, Kuznetsov G, Littlefield BA. Tubulin isotype screening in cancer therapy using halichondrin B analogs. US20060154312; 2006
   Google Scholar
• Ferlini C, Raspaglio G, Mozzetti S, et al. The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 2005;65:2397-405
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33
   PubMed Web of Science ®Google Scholar
• Verrills NM, Flemming CL, Liu M, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003;10:597-607
   PubMed Web of Science ®Google Scholar
• Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on α, β-tubulin by electron crystallography. Science 2004;305:866-9
   PubMed Web of Science ®Google Scholar
• Feyen F, Cachoux F, Gertsch J, et al. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res 2008;41:21-31
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007;18(Suppl 5):v9-v15
   PubMed Web of Science ®Google Scholar
• Larkin JMG, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;18(Suppl 5):v28-34
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Methods of administering epothilone analogs for the treatment of cancer. EP1938821; 2008
   Google Scholar
• Lee FYF, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-12
   PubMed Web of Science ®Google Scholar
• Donovan D, Vahdat LT. Epothilones: clinical update and future directions. Oncology (Williston Park) 2008;22:408-16
   Google Scholar
• Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14
   PubMed Web of Science ®Google Scholar
• Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008;13:214-21
   PubMed Web of Science ®Google Scholar
• Higa GM, Abraham J. Ixabepilone: a new microtubule-targeting agent for breast cancer. Expert Rev Anticancer Ther 2008;8:671-81
   PubMed Web of Science ®Google Scholar
• O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:1045-54
   Google Scholar
• Hoffman J, Fichtmer I, Lemm M, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009;11:158-66
   Google Scholar
• Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J Org Chem 1990;55:4912-5
   Web of Science ®Google Scholar
• Longley RE, Caddigan D, Harmody D, et al. Discodermolide–a new, marine-derived immunosuppressive compound. II. In vivo studies. Transplantation 1991;52:656-61
   PubMedGoogle Scholar
• Gunasekera M, Gunasekera SP, Longley RE, Burres N. Discodermolide compounds, compositions containing same and methods of preparation and use. WO9101982; 1991
   Google Scholar
• ter Haar E, Kowalski RJ, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996;35:243-50
   PubMed Web of Science ®Google Scholar
• Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol 1996;3:287-93
   PubMedGoogle Scholar
• Kowalski RJ, Giannakakou P, Gunasekera SP, et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nudeation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997;52:613-22
   PubMed Web of Science ®Google Scholar
• Kalesse M. The chemistry and biology of discodermolide. ChemBioChem 2000;1:171-5
   Google Scholar
• Balachandran R, ter Haar E, Welsh MJ, et al. The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells–preliminary comparisons to paclitaxel. Anticancer Drugs 1998;9:67-76
   Google Scholar
• Longley RE, Gunasekera SP, Pomponi S. Discodermolide compounds and pharmaceutical compositions containing them for cancer therapy. WO9720835; 1997
   Google Scholar
• Klein LE, Freeze BS, Smith III AB, Horwitz SB. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 2005;4:501-7
   PubMed Web of Science ®Google Scholar
• Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000;6:1978-87
   PubMed Web of Science ®Google Scholar
• Horwitz SB, McDaid HM, Martello LA. Method for treating neoplasia using combination chemotherapy. US20020065234; 2002
   Google Scholar
• Honore S, Kamath K, Braguer D, et al. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 2004;64:4957-64
   PubMed Web of Science ®Google Scholar
• Huang GS, Lopez-Barcons L, Freeze BS, et al. Potentiation of taxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin Cancer Res 2006;12:298-304
   Google Scholar
• Paterson I, Florence GJ. The development of a practical total synthesis of discodermolide, a promising microtubule-stabilizing anticancer agent. Eur J Org Chem 2003;12:2193-208
   Web of Science ®Google Scholar
• Mickel SJ. Toward a commercial synthesis of (+)-discodermolide. Curr Opin Drug Discov Dev 2004;7:869-81
   Google Scholar
• Shaw SJ, Sundermann KF, Burlingame MA, et al. Toward understanding how the lactone moiety of discodermolide affects activity. J Am Chem Soc 2005;127:6532-3
   PubMed Web of Science ®Google Scholar
• Shaw SJ, Menzella HG, Myles DC, et al. Coumarin-derived discodermolide analogues possessing equivalent antiproliferative activity to the natural product—a further simplification of the lactone region. Org Biomol Chem 2007;5:2753-5
   Google Scholar
• Smith III AB, Freeze BS, LaMarche MJ, et al. Design, synthesis, and evaluation of carbamate-substituted analogues of (+)-discodermolide. Org Lett 2005;7:311-4
   PubMed Web of Science ®Google Scholar
• Isbrucker RA, Gunasekera SP, Longley RE. Structure-activity relationship studies of discodermolide and its semisynthetic acetylated analogs on microtubule function and cytotoxicity. Cancer Chemother Pharmacol 2001;48:29-36
   PubMedGoogle Scholar
• Gunasekera SP, Longley RE, Isbrucker RA. Acetylated analogues of the microtubule-stabilizing agent discodermolide: preparation and biological activity. J Nat Prod 2001;64:171-4
   PubMedGoogle Scholar
• Gunasekera SP, Paul GK, Longley RE, et al. Five new discodermolide analogues from the marine sponge Discodermia species. J Nat Prod 2002;65:1643-8
   Google Scholar
• Jiang W, Kumar S, Robertson R, Wong S-M. Discodermolide compositions. US20070082945; 2007
   Google Scholar
• Mita A, Lockhart AC, Chen T-L, et al. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 weeks to adult patients with advanced solid malignancies. J Clin Oncol 2004;22:2025
   Google Scholar
• Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54:72-84
   PubMedGoogle Scholar
• Pettit GR, Cichacz ZA, Gao F, et al. Isolation and structure of the cancer cell growth inhibitor dicyostatin 1. J Chem Soc Chem Commun 1994;1994:1111-2
   Google Scholar
• Pettit GR, Cichacz ZA. Isolation and structure of dictyostatin 1 and its use as anti-neoplastic agent. EP0680958; 1995
   Google Scholar
• Isbrucker RA, Cummins J, Pomponi SA, et al. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem Pharmacol 2003;66:75-82
   PubMed Web of Science ®Google Scholar
• Madiraju C, Edler MC, Hamel E, et al. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry 2005;44:15053-63
   PubMed Web of Science ®Google Scholar
• Florence GJ, Gardner NM, Paterson I. Development of practical syntheses of the marine anticancer agents discodermolide and dictyostatin. Nat Prod Rep 2008;25:342-75
   PubMed Web of Science ®Google Scholar
• Lindel T, Jensen PR, Fenical W, et al. Eleutherobin, a new cytotoxin class that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc 1997;119:8744-5
   Web of Science ®Google Scholar
• Long BH, Carboni JM, Wasserman AJ, et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol®). Cancer Res 1998;58:1111-5
   PubMed Web of Science ®Google Scholar
• Ciomei M, Albanese C, Pastori W, et al. Sarcodictyins: a new class of marine derivatives with mode of action similar to taxol [abstract 30]. Proc Am Assoc Cancer Res 1997;38:5
   Google Scholar
• Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999;38:5490-8
   PubMed Web of Science ®Google Scholar
• Nicolaou KC, Vandelft F, Hosokawa S, et al. Sarcodictyin and eleutherobin useful for stabilizing microtubules. WO9921862; 1999
   Google Scholar
• Andersen RJ, Roberge M, Britton RA, de Silva ED. Antimitotic eleuthesides. WO0300711; 2003
   Google Scholar
• Battistini C, Ciomei M, Pietra F, et al. Terpenoidic derivatives useful as antitumor agents. US5869514; 1999
   Google Scholar
• Mongelli N, Menichincheri M, Ciomei M, et al. Simplified sarcondictyin derivatives as anti-tumor agents. US20050038112; 2005
   Google Scholar
• Mooberry SL, Tien G, Hernandez AH, et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stubilizing agents. Cancer Res 1999;59:653-60
   PubMed Web of Science ®Google Scholar
• Corley DG, Herb R, Moore RE, et al. Laulimalide. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J Org Chem 1988;53:3644-6
   Web of Science ®Google Scholar
• Mooberry SL, Davidson BS. Laulimalide microtubule stabilizing agents. US20020198256; 2002
   Google Scholar
• Pryor DE, O'Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109-15
   PubMed Web of Science ®Google Scholar
• Pineda O, Farrás J, Maccari L, et al. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett 2004;14:4825-9
   PubMed Web of Science ®Google Scholar
• Gapud EJ, Bai R, Ghosh AK, Hamel E. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 2004;66:113-21
   PubMed Web of Science ®Google Scholar
• Clark EA, Hills PM, Davidson BS, et al. Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 2006;3:457-67
   PubMed Web of Science ®Google Scholar
• Lu H, Murtagh J, Schwartz EL. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (Taxotere). Mol Pharmacol 2006;69:1207-15
   PubMed Web of Science ®Google Scholar
• Mulzer J, öhler E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity. Chem Rev 2003;103:3753-86
   PubMed Web of Science ®Google Scholar
• Liu J, Towle MJ, Cheng H, et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007;27:1509-18
   PubMed Web of Science ®Google Scholar
• West LM, Northcote PT, Battershill CN. Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000;65:445-9
   PubMed Web of Science ®Google Scholar
• Hood KA, West LM, Rouwé B, et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 2002;62:3356-60
   PubMed Web of Science ®Google Scholar
• Gaitanos TN, Buey RM, Díaz JF, et al. Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 2004;64:5063-7
   PubMed Web of Science ®Google Scholar
• Hamel E, Day BW, Miller JH, et al. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006;70:1555-64
   PubMed Web of Science ®Google Scholar
• Wilmes A, Bargh K, Kelly C, et al. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 2007;4:269-80
   PubMed Web of Science ®Google Scholar
• Huzil JT, Chik JK, Slysz GW, et al. A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol 2008;378:1016-30
   PubMed Web of Science ®Google Scholar
• Sato B, Muramatsu H, Miyauchi M, et al. A new antimitotic substance, FR182877: I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 2000;53:123-30
   PubMed Web of Science ®Google Scholar
• Sato B, Nakajima H, Hori Y, et al. A new antimitotic substance, FR182877: II. The mechanism of action. J Antibiot 2000;53:204-6
   Google Scholar
• Edler MC, Buey RM, Gussio R, et al. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. Biochemistry 2005;44:11525-8
   Google Scholar
• Buey RM, Calvo E, Barasoain I, et al. Cyclostreptin binds covalently to microtubule pores and luminal taxoid binding sites. Nat Chem Biol 2007;3:117-25
   PubMed Web of Science ®Google Scholar
• Smith III AB, LaMarche MJ, Falcone-Hindley M. Solution structure of (+)-discodermolide. Org Lett 2001;3:695-8
   Google Scholar
• Sánchez-Pedregal VM, Kubicek K, Meiler J, et al. The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide. Angew Chem Int Ed Engl 2006;45:7388-94
   Google Scholar
• Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA 1999;96:4256-61
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000;97:2904-9
   PubMed Web of Science ®Google Scholar
• Ganesh T, Guza RC, Bane S, et al. The bioactive taxol conformation on β-tubulin: Experimental evidence from highly active constrained analogs. Proc Natl Acad Sci USA 2004;101:10006-11
   PubMed Web of Science ®Google Scholar
• Geney R, Sun L, Pera P, et al. Use of the tubulin bound paclitaxel conformation for structure-based rational drug design. Chem Biol 2005;12:339-48
   PubMed Web of Science ®Google Scholar
• Ghosh AK. Microtubule stabilizing compounds. US20030203929; 2003
   Google Scholar
• Bergstralh DT, Ting JP-Y. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006;32:166-79
   PubMed Web of Science ®Google Scholar
• Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998;1:S15-9
   Google Scholar
• Persidis A. Cancer multidrug resistance. Nat Biotechnol 1999;17:94-5
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Nooter K. Dose P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist Updat 2000;3:357-63
   PubMed Web of Science ®Google Scholar